Sugi Predict
/ Targets
/ CHEK2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to CHEK2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. |
PHASE2 | WITHDRAWN |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations |
PHASE2 | RECRUITING |
| Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) |
PHASE2 | RECRUITING |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations |
PHASE2 | COMPLETED |
| Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd |
PHASE2 | COMPLETED |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation |
PHASE2 | RECRUITING |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy |
PHASE2 | COMPLETED |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer |
PHASE1/PHASE2 | COMPLETED |
| Niraparib and Dostarlimab in HRD Solid Tumors |
PHASE2 | UNKNOWN |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors |
PHASE1 | RECRUITING |
| Tabectedin to Treat Children and Adolescents With Cancer |
PHASE1 | COMPLETED |
| A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| M6620 Plus Standard Treatment in Oesophageal and Other Cancer |
PHASE1 | COMPLETED |
| Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors |
PHASE1 | COMPLETED |
| DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy |
nan | RECRUITING |
| Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer) |
nan | COMPLETED |
| Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer |
nan | UNKNOWN |
| Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a CHEK2 binder may also engage these)